PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood.
PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood, for the treatment of sepsis. Sepsis, a life-threatening condition that commonly presents itself as a blood-borne infection, is the number one cause of death in the ICU and is the largest cost on their healthcare system. PATH EX is taking a novel approach by capturing and removing intact bacteria from the blood rather than trying to kill the infection with broad spectrum antibiotics. The PATH EX device is effective regardless of bacteria type or drug resistance. The PATH EX technology has the potential to reduce diagnostic times, treatment costs, readmission rates, and sepsis related deaths.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 21, 2020 | Non-Equity Assistant | $100K | 1 | MassChallenge Texas | — | Detail |
Aug 16, 2018 | Grant | $1.29M | 1 | National Science Foundation | — | Detail |
Jul 10, 2017 | Grant | $225K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
MassChallenge Texas | Yes | Non-Equity Assistant |
National Science Foundation | Yes | Grant |